| Wendy F. DiCicco |
Wendy F. DiCicco currently works at EyePoint Pharmaceuticals, Inc., as Independent Director from 2019, National Association of Corporate Directors (Philadelphia), as Director, Imvax, Inc., as Director from 2020, ExpressCells, Inc., as Director from 2020, The American Institute of Certified Public Accountants, as Member, National Association of Corporate Directors (Virginia), as Member, Pennsylvania Institute of Certified Public Accountants, as Member, Women Corporate Directors, as Member, The CFO Alliance, as Member, Akari Therapeutics Plc, as Chief Financial Officer from 2023, and FerGene, Inc., as Chief Financial Officer. Ms. DiCicco also formerly worked at Coherent Corp., as Independent Director from 2011 to 2017, Golden Dragon Holding Co., as Director, SynCardia Systems LLC, as Independent Director from 2015 to 2016, SWK Holdings Corp., as Independent Director from 2022 to 2023, CannaPharmaRx, Inc., as Independent Director from 2015 to 2016, Carmell Regen Med Corp., as Director from 2018 to 2021, Sincerus Pharmaceuticals, Inc., as Director from 2021 to 2022, DSM Biomedical, Inc., as Chief Financial Officer from 1996 to 2008, Globus Medical, Inc., as Chief Financial Officer from 2008 to 2009, Quench USA, Inc., as Chief Financial Officer from 2010 to 2011, Centinel Spine LLC, as Chief Financial & Operating Officer from 2017 to 2018, Deloitte & Touche LLP, as Staff Accountant & Senior Accountant from 1990 to 1996, Deloitte LLP (New York), as Manager-Accounting & Audit in 1996, Financial Executives International, as Member, Nuron Biotech, Inc., as Chief Financial Officer, Treasurer & VP from 2012 to 2014, Camber Spine Technologies LLC, as President & Chief Operating Officer from 2014 to 2017, Renovacor Holdings, Inc., as Chief Financial Officer, and Renovacor, Inc., as Chief Financial Officer from 2019 to 2022. Ms. DiCicco received her undergraduate degree from Thomas Jefferson University. |
| Miles Nunn |
Miles Nunn is currently the Chief Scientific Officer at Akari Therapeutics Plc since 2015. Prior to this, he worked as a Director at Amplion Ltd., a Scientific Research Manager at Evolutec Group Plc, and as the Chief Scientific Officer at Volution Immuno Pharmaceuticals SA. Dr. Nunn holds a doctorate degree from the University of Oxford and an undergraduate degree from University College London. |
| Raymond Prudo-Chlebosz |
Raymond Prudo-Chlebosz is the founder of Volution Immuno Pharmaceuticals SA (founded in 2008) where he holds the title of Chairman & Chief Executive Officer. He is also the founder of Akari Therapeutics Plc (founded in 2015) where he holds the title of Executive Chairman. Additionally, Dr. Prudo-Chlebosz is the founder of Varleigh Immuno Pharmaceuticals Uk Ltd. (founded in 2007) where he holds the title of Chairman & Chief Executive Officer. Dr. Prudo-Chlebosz is also the founder of The Doctors Laboratory Ltd. Currently, he is working as a Director at Health Services Laboratories LLP. Dr. Prudo-Chlebosz completed his undergraduate degree at the University of London. |
| John F. Neylan |
John F. Neylan is currently the Chief Medical Officer & Executive Vice President at Akari Therapeutics Plc. Prior to this, he was the Chief Medical Officer & Senior Vice President at Keryx Biopharmaceuticals, Inc. from 2015 to 2018. He also held senior positions at Genzyme Corp. and Wyeth Research. Neylan was a Professor at Emory University and an Assistant Professor at the University of California, Davis. He served as the President of The American Society of Transplantation. Neylan received his undergraduate degree from Duke University and his doctorate from Rush Medical College. |
| Melissa Bradford-Klug |
Melissa Bradford-Klug is currently the Chief Executive Officer at Mayfield Pharmaceuticals, Inc. and the Chief Operating Officer at Akari Therapeutics Plc. She previously worked as the Director at Massachusetts Biotechnology Council, Vice President-Corporate Development & Strategy at Mallinckrodt Pharmaceuticals Ltd., Senior VP-Business Development & Strategy at AMAG Pharmaceuticals, Inc., and Chief Business Officer & Senior Vice President at Keryx Biopharmaceuticals, Inc. Ms. Bradford-Klug holds an MBA from DePaul University and an undergraduate degree from Maryville University of St. Louis. |
| Jacques Rachelle Suzanne |
Jacques Rachelle Suzanne is currently the President, Chief Executive Officer & Director at Akari Therapeutics Plc, a Director at Corbus Pharmaceuticals, Inc., an Independent Non-Executive Director at uniQure NV, a Trustee at Alma College, and a Member-Equality Task Force at Alliance for Regenerative Medicine. Previously, Ms. Suzanne served as the Chief Executive Officer at Enzyvant, Inc., the Chief Executive Officer at Enzyvant Therapeutics, Inc., a Director at Viela Bio, Inc., a Vice President-Business Operations at Baxter International, Inc., a Senior Vice President-Global Complement Franchise at Alexion Pharmaceuticals, Inc., a Vice President-Hematology Marketing at Shire Plc, a Vice President-Business Operations at Baxalta, Inc., and worked as a Financial Auditor at Ernst & Young LLP and Deloitte & Touche LLP. Ms. Suzanne obtained an undergraduate degree from Alma College. |
| Michael Grissinger |
Michael Grissinger currently works at Kira Biotech Pty Ltd., as Chairman from 2020, Atrin Pharmaceuticals LLC, as Director from 2018, Akari Therapeutics Plc, as Independent Director from 2018, Aprea Therapeutics, Inc., as Independent Director from 2022, Atriva Therapeutics GmbH, as Director from 2020, and Envisagenics, Inc., as Director. Mr. Grissinger also formerly worked at resTORbio, Inc., as Independent Director from 2018 to 2020, Atrin Pharmaceuticals, Inc., as Director, Janssen Pharmaceuticals, Inc., as Member-Management Board, Johnson & Johnson Ltd., as Vice President-Divestitures, M&A Operations from 1996 to 2018, and Johnson & Johnson, as VP & Head-Pharmaceutical Corporate Development. Mr. Grissinger received his undergraduate degree from Juniata College and Masters Business Admin degree from Fox School of Business. |
| Donald A. Williams |
Donald A. Williams is currently the Chairman at Palisade Bio, Inc. since 2024. He is also the Director at ImpediMed, Inc. since 2017, the Independent Director at Akari Therapeutics Plc since 2016, the Director at Leading Biosciences, Inc. since 2019, and the Independent Director at Forte Biosciences, Inc. since 2020. Previously, Mr. Williams served as the Chairman & President at San Diego Venture Group from 2001 to 2014. He was also the Non-Executive Chairman at ImpediMed Ltd. from 2017 to 2023, the Independent Director at Alphatec Holdings, Inc. from 2015 to 2021, and the Director at Alphatec Spine, Inc. from 2015 to 2021. Additionally, he held the position of Independent Director at Adhera Therapeutics, Inc. from 2014 to 2019 and Director at Proove Biosciences, Inc. from 2015 to 2017. Mr. Williams has a background in business and finance, having worked as the Managing Partner at Grant Thornton LLP from 2007 to 2014. He also held positions at Grant Thornton International Ltd. and Ernst & Young LLP (United Kingdom). Furthermore, he served as a Trustee at CONNECT. Mr. Williams completed his undergraduate degree at Southern Illinois University. |
| Mohamed Wa’el Ahmed Hashad |
Mohamed Wa’el Ahmed Hashad is currently the Chief Executive Officer & Director at Longeveron, Inc., an Independent Director at Akari Therapeutics Plc, and a Director at California Life Sciences Association. Previously, he served as the President & Chief Executive Officer at Avanir Pharmaceuticals, Inc. from 2020 to 2023 and as the Chief Commercial Officer & Executive VP at Seres Therapeutics, Inc. from 2016 to 2017. He holds an undergraduate degree from the University of Pennsylvania, an MBA from the University of Akron, and another undergraduate degree from the University of Cairo. |
